Development of dry powder inhalation system of novel vasoactive intestinal peptide (VIP) analogue for pulmonary administration

Life Sciences

Volumn 79, Issue 2, 2006, Pages 138-143

  Ohmori, Yuki ^a   Onoue, Satomi ^b   Endo, Kosuke ^b   Matsumoto, Asami ^b   Uchida, Shinya ^a   Yamada, Shizuo ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b Ito Life Sciences Inc   (Japan)

Author keywords

Dry powder; IK312532; Lung VIP receptor; Receptor binding; VIP

Indexed keywords

IK 312532; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL TISSUE; ARTICLE; BINDING SITE; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SYNTHESIS; DRY POWDER; LASER DIFFRACTION; LUNG DISEASE; MALE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROTEIN INTERACTION; RAT; SMOOTH MUSCLE; TRACHEA MUSCLE;

ADMINISTRATION, INHALATION; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; INTUBATION, INTRATRACHEAL; IODINE RADIOISOTOPES; LUNG; MALE; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POWDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 33646681248     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2005.12.049     Document Type: Article

References (36)

1. Barnes P.J., and Dixon C.M. The effect of inhaled vasoactive intestinal peptide on bronchial reactivity to histamine in humans. American Review of Respiratory Diseases 130 2 (1984) 162-166
2. Bellinger D.L., Lorton D., Brouxhon S., Felten S., and Felten D.L. The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Advances in Neuroimmunology 6 1 (1996) 5-27
3. Bickel U., Yoshikawa T., Landaw E.M., Faull K.F., and Pardridge W.M. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proceedings of the National Academy of Sciences of the United States of America 90 7 (1993) 2618-2622
4. Caughey G.H., Leidig F., Viro N.F., and Nadel J.A. Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. Journal of Pharmacology and Experimental Therapeutics 244 1 (1988) 133-137
5. Dey R.D., Shannon Jr. W.A., and Said S.I. Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cat, and human subjects. Cell and Tissue Research 220 2 (1981) 231-238
6. Dufes C., Olivier J.C., Gaillard F., Gaillard A., Couet W., and Muller J.M. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. International Journal of Pharmaceutics 255 1-2 (2003) 87-97
7. Endo K., Amikawa S., Matsumoto A., Sahashi N., and Onoue S. Erythritol-based dry powder of glucagons for pulmonary administration. International Journal of Pharmaceutics 290 1-2 (2005) 63-71
8. Fahrenkrug J. Vasoactive intestinal polypeptide: measurement, distribution and putative neurotransmitter function. Digestion 19 3 (1979) 149-169
9. Goetzl E.J., Sreedharan S.P., Turck C.W., Bridenbaugh R., and Malfroy B. Preferential cleavage of amino- and carboxyl-terminal oligopeptides from vasoactive intestinal polypeptide by human recombinant enkephalinase (neutral endopeptidase, EC 3.4.24.11). Biochemical and Biophysical Research Communications 158 3 (1989) 850-854
10. Gomariz R.P., Martinez C., Abad C., Leceta J., and Delgado M. Immunology of VIP: a review and therapeutical perspectives. Current Pharmaceutical Design 7 2 (2001) 89-111
11. Harmar A.J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J.R., Rawlings S.R., Robberecht P., Said S.I., Sreedharan S.P., Wank S.A., and Waschwk J.A. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacological Reviews 50 2 (1998) 265-270
12. Ishihara T., Shigemoto R., Mori K., Takahashi K., and Nagata S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8 4 (1992) 811-819
13. Laitinen A., Partanen M., Hervonen A., Pelto-Huikko M., and Laitinen L.A. VIP like immunoreactive nerves in human respiratory tract. Light and electron microscopic study. Histochemistry 82 4 (1985) 313-319
14. Lam H.C., Takahashi K., Ghatei M.A., Kanse S.M., Polak J.M., and Bloom S.R. Binding sites of a novel neuropeptide pituitary-adenylate-cyclase-activating polypeptide in the rat brain and lung. European Journal of Biochemistry 193 3 (1990) 725-729
15. Leroux P., Vaudry H., Fournier A., St-Pierre S., and Pelletier G. Characterization and localization of vasoactive intestinal peptide receptors in the rat lung. Endocrinology 114 5 (1984) 1506-1512
16. Li L., Luo Z.Q., Zhou F.W., Feng D.D., Guang C.X., Zhang C.Q., and Sun X.H. Effect of vasoactive intestinal peptide on pulmonary surfactants phospholipid synthesis in lung explants. Acta Pharmacologica Sinica 25 12 (2004) 1652-1658
17. Lilly C.M., Kobzik L., Hall A.E., and Drazen J.M. Effects of chronic airway inflammation on the activity and enzymatic inactivation of neuropeptides in guinea pig lungs. Journal of Clinical Investigation 93 6 (1994) 2667-2674
18. Linden A., Hansson L., Andersson A., Palmqvist M., Arvidsson P., Lofdahl C.G., Larsson P., and Lotvall J. Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma. Thorax 58 3 (2003) 217-221
19. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 193 1 (1951) 265-275
20. Merrifield R.B. Solid-phase peptide synthesis. Advances in Enzymology and Related Areas of Molecular Biology 32 (1969) 221-296
21. Morice A., Unwin R.J., and Sever P.S. Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchoconstriction in asthmatic subjects. Lancet 2 8361 (1983) 1225-1227
22. 17]-VIP-GRR (IK312532). Regulatory Peptides 123 1-3 (2004) 201-207
23. Ollerenshaw S., Jarvis D., Woolcock A., Sullivan C., and Scheibner T. Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lungs of patients with asthma. New England Journal of Medicine 320 19 (1989) 1244-1248
24. Onoue S., Ohmori Y., Matsumoto A., Yamada S., Kimura R., Yajima T., and Kashimoto K. Structure-activity relationship of synthetic truncated analogues of vasoactive intestinal peptide (VIP): an enhancement in the activity by a substitution with arginine. Life Sciences 74 12 (2004) 1465-1477
25. Patthi S., Simerson S., and Velicelebi G. Solubilization of rat lung vasoactive intestinal peptide receptors in the active state. Characterization of the binding properties and comparison with membrane-bound receptors. Journal of Biological Chemistry 263 36 (1988) 19363-19369
26. Paul S., and Said S.I. Characterization of receptors for vasoactive intestinal peptide solubilized from the lung. Journal of Biological Chemistry 262 1 (1987) 158-162
27. Rosenthal H.E. A graphic method for the determination and presentation of binding parameters in a complex system. Analytical Biochemistry 20 3 (1967) 525-532
28. Said S.I. Vasoactive peptides in the lung, with special reference to vasoactive intestinal peptide. Experimental Lung Research 3 3-4 (1982) 343-348
29. Sreedharan S.P., Patel D.R., Huang J.X., and Goetzl E.J. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochemical and Biophysical Research Communications 193 2 (1993) 546-553
30. Sumby B., Slater A., Atkins P.J., and Prime D. Review of dry powder inhalers. Advanced Drug Delivery Reviews 26 1 (1997) 51-58
31. Tam E.K., and Caughey G.H. Degradation of airway neuropeptides by human lung tryptase. American Journal of Respiratory Cell and Molecular Biology 3 1 (1990) 27-32
32. Tam E.K., Franconi G.M., Nadel J.A., and Caughey G.H. Protease inhibitors potentiate smooth muscle relaxation induced by vasoactive intestinal peptide in isolated human bronchi. American Journal of Respiratory Cell and Molecular Biology 2 5 (1990) 449-452
33. Urayama A., Yamada S., Deguchi Y., Kimura R., Maeda Y., and Kobayashi T. Brain receptor binding characteristics and pharmacokinetics of JTP-2942, a novel thyrotropin-releasing hormone (TRH) analogue. Life Sciences 65 22 (1999) 2407-2415
34. Urayama A., Yamada S., Hirano K., Deguchi Y., and Kimura R. Brain receptor binding characteristics and pharmacokinetic-pharmacodynamic analysis of thyrotropin-releasing hormone analogue. Life Sciences 70 6 (2001) 647-657
35. 3H]WB4101: effect of 6-hydroxydopamine treatment. Journal of Pharmacology and Experimental Therapeutics 215 1 (1980) 176-185
36. Zeng X.M., Martin A.P., Marriott C., and Pritchard J. The influence of carrier morphology on drug delivery by dry powder inhalers. International Journal of Pharmaceutics 200 1 (2000) 93-106